Affordable Access

deepdyve-link
Publisher Website

No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants

Authors
  • Li, Qianqian1
  • Nie, Jianhui1
  • Wu, Jiajing1
  • Zhang, Li1
  • Ding, Ruxia1
  • Wang, Haixin1
  • Zhang, Yue1
  • Li, Tao1
  • Liu, Shuo1
  • Zhang, Mengyi1
  • Zhao, Chenyan1
  • Liu, Huan1
  • Nie, Lingling1
  • Qin, Haiyang1
  • Wang, Meng1
  • Lu, Qiong1
  • Li, Xiaoyu1
  • Liu, Junkai1
  • Liang, Haoyu1
  • Shi, Yi2
  • And 7 more
  • 1 Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China
  • 2 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing 100101, China
  • 3 Beijing Biocytogen Co., Ltd., Beijing 101111, China
  • 4 Beijing Antibody Research Key Laboratory, Sino Biological Inc., Building 9, Jing Dong Bei Technology Park, No.18 Ke Chuang 10th St, BDA, Beijing, 100176, China
  • 5 Center for Global Health and Infectious Diseases, Comprehensive AIDS Research Center, and Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing 100084, China
  • 6 Translational Medicine Institute, The First People's Hospital of Chenzhou, University of South China, Chenzhou 423000, China
  • 7 National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
Type
Published Article
Journal
Cell
Publisher
Elsevier Inc.
Publication Date
Feb 23, 2021
Identifiers
DOI: 10.1016/j.cell.2021.02.042
PMCID: PMC7901273
Source
PubMed Central
License
Unknown

Abstract

Experiments with pseudotyped viruses show that the 501Y.V2 variant of SARS-CoV-2 exhibits resistance to neutralization from monoclonal antibodies and sera from convalescent as well as immunized individuals, predominantly due to the E484K and N501Y mutations in the receptor-binding domain of the viral spike protein.

Report this publication

Statistics

Seen <100 times